Tag Archives: abbott labs

Centocor v. Abbott Labs. – “Antibody Exception” To Written Description Requirement Under Fire

Abbott Laboratories markets a recombinant human antibody, HUMIRA, as a treatment for rheumatoid arthritis. This antibody binds to a receptor on TNF. NYU and Centocor own US Pat No 7070775 which claims an isolated recombinant anti-TNF-a antibody (Ab) comprising a … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , | Leave a comment